Jing Yang1, Jin He1, Mahmoud Ismail1, Sonja Tweeten1, Fanfang Zeng2, Ling Gao3, Scott Ballinger4, Martin Young1, Sumanth D Prabhu1, Glenn C Rowe1, Jianyi Zhang3, Lufang Zhou1, Min Xie5. 1. Dept. of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL 35233, United States of America. 2. Dept. of Cardiovascular Disease, Shenzhen Sun Yat-Sen Cardiovascular Hospital, 518020, China. 3. Dept. of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL 35233, United States of America. 4. Dept. of Pathology, Division of Molecular and Cellular Pathology, University of Alabama at Birmingham, Birmingham, AL 35233, United States of America. 5. Dept. of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL 35233, United States of America. Electronic address: mxie@uabmc.edu.
Abstract
AIMS: The FDA-approved histone deacetylase (HDAC) inhibitor, suberoylanilide hydroxamic acid (SAHA, Vorinostat) has been shown to induce cardiomyocyte autophagy and blunt ischemia/reperfusion (I/R) injury when administered at the time of reperfusion. However, the precise mechanisms underlying the cardioprotective activity of SAHA are unknown. Mitochondrial dysfunction and oxidative damage are major contributors to myocardial apoptosis during I/R injury. We hypothesize that SAHA protects the myocardium by maintaining mitochondrial homeostasis and reducing reactive oxygen species (ROS) production during I/R injury. METHODS: Mouse and cultured cardiomyocytes (neonatal rat ventricular myocytes and human embryonic stem cell-derived cardiomyocytes) I/R models were used to investigate the effects of SAHA on mitochondria. ATG7 knockout mice, ATG7 knockdown by siRNA and PGC-1α knockdown by adenovirus in cardiomyocytes were used to test the dependency of autophagy and PGC-1α-mediated mitochondrial biogenesis respectively. RESULTS: Intact and total mitochondrial DNA (mtDNA) content and mitochondrial mass were significantly increased in cardiomyocytes by SAHA pretreatment before simulated I/R. In vivo, I/R induced >50% loss of mtDNA content in the border zones of mouse hearts, but SAHA pretreatment and reperfusion treatment alone reverted mtDNA content and mitochondrial mass to control levels. Moreover, pretreatment of cardiomyocytes with SAHA resulted in a 4-fold decrease in I/R-induced loss of mitochondrial membrane potential and a 25%-40% reduction in cytosolic ROS levels. However, loss-of-function of ATG7 in cardiomyocytes or mouse myocardium abolished the protective effects of SAHA on ROS levels, mitochondrial membrane potential, mtDNA levels, and mitochondrial mass. Lastly, PGC-1α gene expression was induced by SAHA in NRVMs and mouse heart subjected to I/R, and loss of PGC-1α abrogated SAHA's mitochondrial protective effects in cardiomyocytes. CONCLUSIONS: SAHA prevents I/R induced-mitochondrial dysfunction and loss, and reduces myocardial ROS production when given before or after the ischemia. The protective effects of SAHA on mitochondria are dependent on autophagy and PGC-1α-mediated mitochondrial biogenesis.
AIMS: The FDA-approved histone deacetylase (HDAC) inhibitor, suberoylanilide hydroxamic acid (SAHA, Vorinostat) has been shown to induce cardiomyocyte autophagy and blunt ischemia/reperfusion (I/R) injury when administered at the time of reperfusion. However, the precise mechanisms underlying the cardioprotective activity of SAHA are unknown. Mitochondrial dysfunction and oxidative damage are major contributors to myocardial apoptosis during I/R injury. We hypothesize that SAHA protects the myocardium by maintaining mitochondrial homeostasis and reducing reactive oxygen species (ROS) production during I/R injury. METHODS: Mouse and cultured cardiomyocytes (neonatal rat ventricular myocytes and human embryonic stem cell-derived cardiomyocytes) I/R models were used to investigate the effects of SAHA on mitochondria. ATG7 knockout mice, ATG7 knockdown by siRNA and PGC-1α knockdown by adenovirus in cardiomyocytes were used to test the dependency of autophagy and PGC-1α-mediated mitochondrial biogenesis respectively. RESULTS: Intact and total mitochondrial DNA (mtDNA) content and mitochondrial mass were significantly increased in cardiomyocytes by SAHA pretreatment before simulated I/R. In vivo, I/R induced >50% loss of mtDNA content in the border zones of mouse hearts, but SAHA pretreatment and reperfusion treatment alone reverted mtDNA content and mitochondrial mass to control levels. Moreover, pretreatment of cardiomyocytes with SAHA resulted in a 4-fold decrease in I/R-induced loss of mitochondrial membrane potential and a 25%-40% reduction in cytosolic ROS levels. However, loss-of-function of ATG7 in cardiomyocytes or mouse myocardium abolished the protective effects of SAHA on ROS levels, mitochondrial membrane potential, mtDNA levels, and mitochondrial mass. Lastly, PGC-1α gene expression was induced by SAHA in NRVMs and mouse heart subjected to I/R, and loss of PGC-1α abrogated SAHA's mitochondrial protective effects in cardiomyocytes. CONCLUSIONS: SAHA prevents I/R induced-mitochondrial dysfunction and loss, and reduces myocardial ROS production when given before or after the ischemia. The protective effects of SAHA on mitochondria are dependent on autophagy and PGC-1α-mediated mitochondrial biogenesis.
Authors: D S Sohal; M Nghiem; M A Crackower; S A Witt; T R Kimball; K M Tymitz; J M Penninger; J D Molkentin Journal: Circ Res Date: 2001-07-06 Impact factor: 17.367
Authors: John J Shacka; Barbara J Klocke; Masahiro Shibata; Yasuo Uchiyama; Geeta Datta; Robert E Schmidt; Kevin A Roth Journal: Mol Pharmacol Date: 2006-01-03 Impact factor: 4.436
Authors: Scott W Ballinger; Cam Patterson; Cynthia A Knight-Lozano; David L Burow; Caryl A Conklin; Zhaoyong Hu; Johannes Reuf; Chris Horaist; Russell Lebovitz; Glenn C Hunter; Ken McIntyre; Marschall S Runge Journal: Circulation Date: 2002-07-30 Impact factor: 29.690
Authors: Christopher L Antos; Timothy A McKinsey; Matthew Dreitz; Lisa M Hollingsworth; Chun-Li Zhang; Kathy Schreiber; Hansjorg Rindt; Richard J Gorczynski; Eric N Olson Journal: J Biol Chem Date: 2003-05-20 Impact factor: 5.157
Authors: Jennifer S Carew; Steffan T Nawrocki; Charissa N Kahue; Hui Zhang; Chunying Yang; Linda Chung; Janet A Houghton; Peng Huang; Francis J Giles; John L Cleveland Journal: Blood Date: 2007-03-15 Impact factor: 22.113
Authors: Min Xie; Geoffrey W Cho; Yongli Kong; Dan L Li; Francisco Altamirano; Xiang Luo; Cyndi R Morales; Nan Jiang; Gabriele G Schiattarella; Herman I May; Jessica Medina; John M Shelton; Anwarul Ferdous; Thomas G Gillette; Joseph A Hill Journal: Circ Res Date: 2021-06-11 Impact factor: 23.213